A key challenge facing health systems today is to identify and avoid unnecessary health innovations and accelerate access to those that are necessary. This process can be guided by applying health economic modelling at the early stages of development of new therapeutics to direct product development, market access, and pricing.
This is very relevant and timely to the field of hearing loss, where biotechnology, pharmaceutical and device companies have identified an unmet market need and have dedicated sizeable investments in the development of novel (drugs, genes, cells) hearing therapeutics.
To assess the potential added value of these novel hearing therapeutics, we will develop an early health economic model comparing novel hearing therapeutics with the current standard of care.
Professor Anne Schilder
Start date and duration
January 2019 – 9 months